Prevalence of undiagnosed prostate cancer in men with erectile dysfunction.
OBJECTIVE
To explore the prevalence of prostate cancer in men presenting with erectile dysfunction (ED).


METHODS
In a prospective study, 127 men with ED of at least 6 months duration underwent screening for prostate cancer using prostate specific antigen (PSA) and a digital rectal examination (DRE). Men with a high PSA level (> 4 ng/mL) had sextant biopsies taken under sedoanalgesia. The serum testosterone level was measured in all the men.


RESULTS
Twenty-six men were aged < 50 years and all had a normal PSA level; of 101 men aged > 50 years, 20 had an abnormal PSA. The detection rate for prostate cancer using PSA and DRE was 5%, which was not significantly higher than in the general population. All the detected cancers were clinically significant (> T2a, Gleason grade > 4). Two of the five men diagnosed with prostate cancer were Afro-Caribbean. Of the 127 men, 31% had a low serum testosterone level, but there was no association between testosterone and PSA levels.


CONCLUSIONS
Prostate cancer is no more common in men with ED than in the normal male population. Therefore, routine screening for prostate cancer in men with ED is not indicated.
Sairam
K
K
Lister Hospital, Stevenage, and Health Research & Development Support Unit (HRDSU), Faculty of Health & Human Sciences, University of Hertfordshire, Hatfield, Herts, UK.
Kulinskaya
E
E
Boustead
G B
GB
Hanbury
D C
DC
McNicholas
T A
TA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D007172:Erectile Dysfunction / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010808:Physical Examination; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications*; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D017430:Prostate-Specific Antigen